Cost-effective non-additive GWAS across 2329 diseases in 500,349 individuals
Abstract Drug candidates supported by genetic evidence are more likely to succeed in clinical trials, with genome-wide association studies (GWAS) providing a key source of such evidence. Standard GWAS approaches assume additive effects of alleles on the phenotype, but non-additive models have also s...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Portfolio
2025-12-01
|
| Reeks: | Nature Communications |
| Online toegang: | https://doi.org/10.1038/s41467-025-67277-4 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|